Background: Acute kidney injury (AKI) following cardiac surgery is common and associated with poor patient outcomes. Early risk assessment for development of AKI remains a challenge. The combination of urinary tissue inhibitor of metalloproteinase 2 (TIMP-2) and insulin-like growth factor binding protein 7 (IGFBP7) has been shown to be an excellent predictor of AKI following cardiac surgery, but reported studies are for predominately non-Asian populations. 
Background
Acute kidney injury (AKI) is a global health concern associated with increased morbidity and mortality [1] [2] [3] . Patients undergoing cardiac surgery, especially with cardiopulmonary bypass, are at high risk for AKI. A recent meta-analysis estimated the global incidence of AKI following cardiac surgery to be approximately 22% [4] . Development of AKI following cardiac surgery increases hospital and ICU length of stage, short and long term mortality, and risk of long-term renal dysfunction [4] [5] [6] .
Despite the adverse consequences associated with AKI, missed or delayed diagnosis of AKI is common [7, 8] . Early diagnosis of AKI requires close monitoring of changes in serum creatinine and urine output, which may not be practical for all patients. Additionally, changes in these markers of renal function often lag injury [9] . Risk assessment for AKI is recommended by clinical practice guidelines to facilitate early detection of AKI and potentially prevent AKI in some cases [10] . Yet, few tools for early risk assessment are available beyond clinical evaluation.
Recently, a biomarker-based test for AKI risk assessment has become available for clinical use in Europe and the United States [11] . The test measures two urinary proteins involved in cell-cycle arrest: tissue inhibitor of metalloproteinase 2 (TIMP-2) and insulin-like growth factor-binding protein 7 (IGFBP7). These urinary cell cycle arrest markers are believed to be indicators of renal tubule cell stress involved in the earliest phases of acute kidney injury [12] . The combination of these biomarkers ([TIMP-2]•[IGFBP7]) has been shown to be predictive of AKI in large diverse cohorts of critically ill patients in the Sapphire, Opal and Topaz studies [12] [13] [14] .
Studies 
Methods

Study design and participants
We conducted a prospective observational study after obtaining approval from the institutional review board of the ethics committee of Zhongshan Hospital. Adult patients were screened for enrollment prior to cardiac surgery at Zhongshan Hospital in Shanghai, China, between May 01, 2016 to May 31, 2016. All enrolled patients provided written informed consent. Exclusion criteria were age less than 18 years, chronic dialysis, and prior renal transplantation. Urine samples for measurement of [TIMP-2]•[IGFBP7] were collected prior to surgery, in 2-h intervals from 0 h to 12 h after ICU admission, and 24 h after ICU admission to characterize the time-profile of [TIMP-2]•[IGFBP7]. Clinical data for the study were abstracted from hospital records and included patient demographics, medical history, surgical procedure, and serum creatinine and urine output data for AKI assessment.
Endpoints
The primary endpoints were AKI and moderate-tosevere AKI within 7 days following surgery. AKI was defined according to the Kidney Disease: Improving Global Outcomes (KDIGO) criteria [10] . Moderate-tosevere AKI was defined as KDIGO stage 2 or 3 AKI. As in prior studies of cardiac surgery patients [15, 17, 18] , both urine output and serum creatinine were used to determine AKI stages. Serum creatinine results from blood samples collected at hospital admission were used as the baseline values for AKI staging.
Urine sample analysis
Urine samples were analyzed for TIMP-2 and IGFBP7 within 1 h of collection using the NephroCheck Test and Astute140 Meter (Astute Medical, San Diego, CA values at each urine sample collection time were determined for endpoint positive and endpoint negative patients. Categorical variables were compared between groups using Fisher exact test. Continuous variables were compared using the Wilcoxon rank-sum test. Two-sided P -values <0.05 were considered statistically significant. Statistical analyses were performed using SAS 9.4 (SAS Institute, Cary, NC). A clinical risk model for prediction of AKI was constructed starting from all clinical variables significantly (P < 0.05) associated with AKI ( Table 1) . Goodness of fit was assessed with the Hosmer-Lemeshow test. Category free net reclassification improvement (cfNRI), integrated discrimination improvement (IDI), and AUC difference were used to assess the improvement in predictive ability with the addition of [TIMP-2]•[IGFBP7] to the model.
Results
Patient characteristics
We enrolled 57 cardiac surgery patients. Twenty (35.1%) patients developed AKI within 7 days of surgery, and 6 (10.5%) patients developed stage 2-3 AKI. Two patients with stage 3 AKI received renal replacement therapy. Compared with patients who did not develop AKI, AKI patients were older, more likely to be male, and more likely to have a history of hypertension and hyperlipidemia (Table 1) . AKI patients had higher preoperative serum creatinine levels, more recent exposure to radiocontrast agents, and were more likely to have undergone aortic valve replacement than non-AKI patients. Though not statistically significant (P = 0.06), cardiopulmonary bypass was more common among AKI patients than non-AKI patients. the high specificity cutoff of 2.0. The sensitivity was 75% for any AKI and 100% for stage 2-3 AKI at the 0.3 cutoff, and the specificity was 100% for any AKI and 96% for stage 2-3 AKI at the 2.0 cutoff. The NPV was 84% for any AKI and 100% for stage 2-3 AKI at the 0.3 cutoff, and the PPV was 100% for any AKI and 50% for stage 2-3 AKI at the 2.0 cutoff. 
Biomarker time course
Clinical model
A clinical risk model for the prediction of AKI was constructed using backward selection. The selected variables were sex, hypertension and preoperative serum creatinine ( [12, 14, 20, 21] . Major surgery [15, 18] . Second, patients should be starting to stabilize at this time, and it is therefore a good time to evaluate which patients may be experiencing increased renal tubule cell stress, putting them at risk for developing a serious post-operative AKI complication. Such patients are good candidates to receive preventive measures that have been outlined in the KDIGO guideline [10] and elsewhere [20] for high-risk patients.
In our study, [TIMP-2]•[IGFBP7] measured in urine collected 4 h after ICU admission was predictive of both any stage of AKI and stage 2-3 AKI. The sensitivity at the previously validated 0.3 cutoff was 75% for any AKI and 100% for stage 2-3 AKI, and the specificity at the previously validated 2.0 cutoff was 100% for any AKI and 96% for stage 2-3 AKI.
Multiple studies in Germany have investigated urinary [TIMP-2]•[IGFBP7] for prediction of AKI following cardiac surgery in adults [15, 17, 18] . These studies either specifically enrolled patients undergoing coronary artery bypass graft (CABG) surgery or enrolled cardiac surgery patients deemed to be high risk for AKI as defined by a Cleveland Clinic Foundation Score [22] ≥ 6. Unlike in these studies, we did not restrict our enrolled cohort by type of cardiac surgery or pre-surgery risk. Yet, our results are strikingly similar to those of these other studies. In the CABG study, for which the endpoint was stage 2-3 AKI, the AUC (95% CI) of urinary [TIMP-2]•[IGFBP7] at 4 h after surgery was 0.86 (0.72-1.00) as compared to 0.83 (0.69-0.96) at 4 h after ICU admission for the same endpoint in our study. Our study also found that preoperative serum creatinine was significantly higher in AKI group and it is a risk factor for the prediction of AKI after cardiac surgery similar to previous studies in which subjects with higher serum creatinine developed acute or chronic kidney dysfunction after surgery [22, 23] . Of course the combination of creatinine and biomarkers is the future of AKI prediction. It is important to note that clinical risk prediction models derived from small data sets such as ours are "overtrained" and their performance thus overestimated. [17, 24] have shown maximum predictive ability the morning after surgery. Although it is usually assumed that the earliest injury in cardiac surgery associated AKI occurs during the surgery, it is possible in some patients that significant postoperative kidney exposures such as episodes of hypotension, developing infections or nephrotoxic drugs cause kidney stress and AKI to start developing during the post-operative period. This may explain why the maximum predictive ability of [TIMP-2]•[IGFBP7] occurred early after surgery in some studies (including ours) and later in other studies. This hypothesis requires additional investigation, but suggests that repeated testing might be appropriate in cases in which significant post-operative exposures might exist. Indeed, one study [15] found that use of three measurements (4, 12 and 24 h after CPB) had greater predictive value (AUC = 0.90) than a single measurement 4 h after CBP (AUC = 0.81).
Although all patients experiencing significant kidney exposures are at increased risk of AKI, only a small fraction (about 10% in our study) will develop the severest forms of AKI (stage 2-3). The [TIMP-2]•[IGFBP7] test provides a quantitative indication of risk (renal tubule cell stress) for each particular patient, with higher test values indicating higher stress and thus higher risk. Two wellestablished cutoffs, one at 0.3 that is highly sensitive and one at 2.0 that is highly specific provide risk stratification that allows the physician to apply preventative measures such as enhanced hemodynamic monitoring and modified drug dosing commensurate with the risk level [20] . Our study for the first time verifies these cutoffs in a Chinese population. Therefore, we can expect that protocols developed in other countries for using the test to help manage patients at risk for AKI will be relevant to patients undergoing cardiac surgery in China.
Conclusions
The prediction performance of urine [TIMP-2]•[IGFBP7] in a Chinese cardiac surgery population is good for all of the AKI patients, not just stage 2-3 AKI. It is even better than that reported previously in non-Asian populations. 
